• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran,
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Background A polypill that includes key medications associated with improved outcomes
(aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as …

Background The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab
produced coronary atheroma regression in statin-treated patients. Objectives The purpose of …

Background European data pre-2019 suggest statin monotherapy is the most common
approach to lipid management for preventing cardiovascular (CV) events, resulting in only …

Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …

Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …

Background Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL
cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into …

Background MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase
subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia …